Northstar Asset Management Lowers stake in Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (TMO) : Northstar Asset Management reduced its stake in Thermo Fisher Scientific by 2.85% during the most recent quarter end. The investment management company now holds a total of 48,659 shares of Thermo Fisher Scientific which is valued at $7,151,413 after selling 1,425 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on May 2, 2016.Thermo Fisher Scientific makes up approximately 3.06% of Northstar Asset Management’s portfolio.

Thermo Fisher Scientific opened for trading at $145 and hit $147.53 on the upside on Friday, eventually ending the session at $146.97, with a gain of 1.26% or 1.83 points. The heightened volatility saw the trading volume jump to 12,57,404 shares. Company has a market cap of $58,239 M.

Other Hedge Funds, Including , Hl Financial Services boosted its stake in TMO in the latest quarter, The investment management firm added 115 additional shares and now holds a total of 1,856 shares of Thermo Fisher Scientific which is valued at $267,728. Thermo Fisher Scientific makes up approx 0.01% of Hl Financial Services’s portfolio.Pacwest Financial Management Inc reduced its stake in TMO by selling 255 shares or 2.52% in the most recent quarter. The Hedge Fund company now holds 9,878 shares of TMO which is valued at $1,424,902. Thermo Fisher Scientific makes up approx 0.92% of Pacwest Financial Management Inc’s portfolio.Lathrop Investment Management Corp boosted its stake in TMO in the latest quarter, The investment management firm added 440 additional shares and now holds a total of 92,916 shares of Thermo Fisher Scientific which is valued at $13,644,715. Thermo Fisher Scientific makes up approx 4.30% of Lathrop Investment Management Corp’s portfolio.First Quadrant L Pca reduced its stake in TMO by selling 5,860 shares or 4.79% in the most recent quarter. The Hedge Fund company now holds 116,516 shares of TMO which is valued at $17,110,375. Thermo Fisher Scientific makes up approx 0.37% of First Quadrant L Pca’s portfolio.

On the company’s financial health, Thermo Fisher Scientific reported $1.80 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.74. The company had revenue of $4294.80 million for the quarter, compared to analysts expectations of $4113.28 million. The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.63 EPS.

Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on May 3, 2016 to “Buy”, Firm has raised the Price Target to $ 163 from a previous price target of $160 .Thermo Fisher Scientific was Downgraded by Jefferies to ” Hold” on Apr 29, 2016. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .

Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.

Leave a Reply

Thermo Fisher Scientific - Is it time to Sell?

Top Brokerage Firms are advising their investors on Thermo Fisher Scientific. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.